VB10.16

Outline of further clinical development in HPV16-positive malignancies

December 20, 2022

Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Nykode Therapeutics | VB10.16 development plan | Non -confidential

2

Today's presenters from Nykode management

MICHAEL ENGSIG

Chief Executive

Officer

Wide-ranging experience from leading early-stage drug discovery through late-stage and

commercial development​

  • Takeda
    and Nycomed
  • PPD​
  • KLIFO​

AGNETE FREDRIKSEN

Chief Business Officer & Co-founder

More than 20 years experience with APC- targeted vaccines from drug discovery to clinical development in various leadership positions at

  • Vaccibody/Nykode

KLAUS EDVARDSEN

Chief Development Officer

Extensive experience from leading drug development programs within oncology, hematology and infectious

diseases in ​both biotech and pharma companies:

  • CureVac​ (as CDO)
  • Merck KGaA
  • AstraZeneca

Nykode Therapeutics | VB10.16 development plan | Non -confidential

3

VB C-02: VB10.16 + Atezolizumab (Tecentriq®) in advanced Cervical Cancer - Study on track

  1. Multi-Centre,Single Arm, Open-label Phase 2a Trial of the Combination of VB10.16 and atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16 Positive Cervical Cancer (NCT04405349)
  • Objectives: safety/tolerability, immunogenicity and efficacy
  • Primary endpoints: incidence/severity of AEs, ORR (based on RECIST 1.1 by blinded independent central review)
  • Fully enrolled with 52 patients
  • Conducted in Europe in 6 countries (Germany, Belgium, Bulgaria, Czech Republic, Poland and Norway)
  • Enrolled patients received treatment with 3 mg VB10.16 in combination with 1200 mg atezolizumab for up to 48 weeks

Advanced

12 MONTHS

or recurrent,

Vaccination

Vaccination

non-respectable

HPV16-positive

induction

maintenance

cervical cancer

12 MONTHS

Follow-up

Nykode Therapeutics | VB10.16 development plan | Non -confidential

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Nykode Therapeutics AS published this content on 20 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 December 2022 10:16:18 UTC.